Ultragenyx Pharma (RARE) Misses Q4 EPS by 28c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.42), $0.28 worse than the analyst estimate of ($1.14).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print